Big pharma against CL move but WHO agrees

  • Nation Premium
  • Friday, 02 Mar 2018

Right to get treatment: It was reported last year that there were 400,000 Hepatitis C sufferers in Malaysia, with only a fraction who could afford the RM300,000 cost. — AFP

KUALA LUMPUR: Malaysia’s bold move to impose compulsory licence (CL) on the drug sofosbuvir has been heavily criticised by big pharmaceutical companies, but has the support of the World Health Organisation (WHO).

WHO advocates universal health coverage and that means access to life-saving treatment, said its head of mission and representative to Malaysia, Brunei and Singapore Dr Lo Ying-Ru.

Article type: metered
User access status: 3
Join our Telegram channel to get our Evening Alerts and breaking news highlights

Next In Nation

Where is Najib? Why is he not in court? Judge orders proceedings to continue in the afternoon Premium
Bank manager killed after car crashes into lorry Premium
Almost 1,000 M’sians granted Fulbright scholarships since 1963, says Higher Education Minister Premium
High Court orders Paul Yong to enter defence on rape charge Premium
Covid-19 Watch: 86.6% adolescents in Malaysia vaccinated Premium
Businessman cheated of RM11,600 in online scam Premium
Najib seeks to postpone application hearing and decision after Covid-19 strikes legal team Premium
Issues on rising price of goods focus of Dewan Rakyat on Tuesday (Dec 7) Premium
Pool party nets RM1.5mil in fines Premium
Jetty collapse leaves commuters in the lurch Premium

Others Also Read